228 related articles for article (PubMed ID: 21487429)
1. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.
Duiker EW; Meijer A; van der Bilt AR; Meersma GJ; Kooi N; van der Zee AG; de Vries EG; de Jong S
Br J Cancer; 2011 Apr; 104(8):1278-87. PubMed ID: 21487429
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines.
Van Geelen CM; Pennarun B; Ek WB; Le PT; Spierings DC; De Vries EG; De Jong S
Int J Oncol; 2010 Oct; 37(4):1031-41. PubMed ID: 20811726
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
Duiker EW; de Vries EG; Mahalingam D; Meersma GJ; Boersma-van Ek W; Hollema H; Lub-de Hooge MN; van Dam GM; Cool RH; Quax WJ; Samali A; van der Zee AG; de Jong S
Clin Cancer Res; 2009 Mar; 15(6):2048-57. PubMed ID: 19276284
[TBL] [Abstract][Full Text] [Related]
4. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL.
Meijer A; Kruyt FA; van der Zee AG; Hollema H; Le P; ten Hoor KA; Groothuis GM; Quax WJ; de Vries EG; de Jong S
Br J Cancer; 2013 Nov; 109(10):2685-95. PubMed ID: 24136147
[TBL] [Abstract][Full Text] [Related]
5. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
[TBL] [Abstract][Full Text] [Related]
6. Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents.
Moxley KM; Chengedza S; Benbrook DM
Gynecol Oncol; 2009 Dec; 115(3):438-42. PubMed ID: 19804900
[TBL] [Abstract][Full Text] [Related]
7. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
[TBL] [Abstract][Full Text] [Related]
8. Human papilloma virus 16 E6 RNA interference enhances cisplatin and death receptor-mediated apoptosis in human cervical carcinoma cells.
Tan S; Hougardy BM; Meersma GJ; Schaap B; de Vries EG; van der Zee AG; de Jong S
Mol Pharmacol; 2012 May; 81(5):701-9. PubMed ID: 22328720
[TBL] [Abstract][Full Text] [Related]
9. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):404-11. PubMed ID: 26463141
[TBL] [Abstract][Full Text] [Related]
10. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
11. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
12. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
[TBL] [Abstract][Full Text] [Related]
13. β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK.
Li QQ; Lee RX; Liang H; Wang G; Li JM; Zhong Y; Reed E
Int J Oncol; 2013 Sep; 43(3):721-8. PubMed ID: 23817665
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.
Bräutigam K; Biernath-Wüpping J; Bauerschlag DO; von Kaisenberg CS; Jonat W; Maass N; Arnold N; Meinhold-Heerlein I
J Cancer Res Clin Oncol; 2011 May; 137(5):875-86. PubMed ID: 20878528
[TBL] [Abstract][Full Text] [Related]
16. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.
Hougardy BM; Maduro JH; van der Zee AG; de Groot DJ; van den Heuvel FA; de Vries EG; de Jong S
Int J Cancer; 2006 Apr; 118(8):1892-900. PubMed ID: 16287099
[TBL] [Abstract][Full Text] [Related]
18. Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.
Karaca B; Atmaca H; Bozkurt E; Kisim A; Uzunoglu S; Karabulut B; Sezgin C; Sanli UA; Uslu R
Mol Biol Rep; 2013 Jun; 40(6):3925-33. PubMed ID: 23269627
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
Bullenkamp J; Raulf N; Ayaz B; Walczak H; Kulms D; Odell E; Thavaraj S; Tavassoli M
Cell Death Dis; 2014 Oct; 5(10):e1489. PubMed ID: 25341043
[TBL] [Abstract][Full Text] [Related]
20. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
Ma JJ; Chen BL; Xin XY
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]